Quick Facts: Zilden (Diltiazem) Therapeutic Uses

• Chronic Stable Angina: May contribute to improved exercise capacity and tolerance in patients.
• Hypertension (High Blood Pressure): An available option for the management of high blood pressure.
• Certain Heart Rhythm Disorders: May be used for temporary control of rapid ventricular rate in conditions like atrial fibrillation or atrial flutter.

---

Zilden (Diltiazem) is a prescription medical option used in the management of several cardiovascular conditions. Its primary role involves supporting the health and function of the heart and circulatory system.

For individuals with chronic stable angina (chest pain), Zilden may help to improve physical endurance and reduce the frequency of uncomfortable episodes. It is indicated to address the symptoms associated with this condition.

In the management of hypertension, Zilden is an option that may help to control and lower elevated blood pressure levels. Maintenance of appropriate blood pressure is part of a comprehensive cardiovascular risk management plan.

Additionally, Zilden is used in a hospital setting for the temporary control of rapid ventricular rate in specific heart rhythm disorders, such as atrial fibrillation or atrial flutter.

Regulatory References

1. NIH MedlinePlus guidance

Diltiazem is generally indicated for adult patients but is strictly prohibited or restricted in several populations based on regulatory labeling.

Contraindicated Populations

Use of Diltiazem is contraindicated in patients with:

• Sick Sinus Syndrome or Second- or Third-Degree AV Block (except with a functioning ventricular pacemaker).
• Severe Hypotension (e.g., systolic blood pressure <90 mmHg) or Cardiogenic Shock.
• Acute Myocardial Infarction with Pulmonary Congestion.
• Atrial Fibrillation/Flutter associated with an Accessory Bypass Tract (e.g., Wolff-Parkinson-White syndrome).
• Known Hypersensitivity to the drug.

---

Age and Condition Restrictions

Population Group	Eligibility Status (Regulatory Wording)
Pediatric Patients	Not recommended; safety and efficacy not established.
Elderly Patients	Use with caution; a lower starting dose may be necessary.
Hepatic Impairment	Use with caution; requires careful monitoring.
Renal Impairment	Use with caution; requires monitoring and potential dosage adjustment.
Pregnancy/Lactation	Contraindicated or not recommended (excreted in human milk).

Interactions with other medicines and products

Official regulatory information for Diltiazem is structured by its documented effects on drug metabolism and cardiac function. Diltiazem is classified as an inhibitor of the Cytochrome P450 3A4 (CYP3A4) enzyme and the P-glycoprotein (P-gp) drug transporter. This pharmacokinetic interaction typically results in an increased plasma concentration and exposure of many co-administered medicines that are substrates for these pathways, including certain statins (like Simvastatin), immunosuppressants (like Cyclosporine), and benzodiazepines (like Midazolam).

Interaction Type	Examples of Affected Substances
Pharmacodynamic	Beta-blockers, Digoxin, Amiodarone, Anesthetics (Risk of additive bradycardia and heart block).
Exposure Modifiers	Cimetidine (increases Diltiazem exposure); Rifampin (decreases Diltiazem exposure).

Co-administration with intravenous Dantrolene and Ivabradine is formally contraindicated in some regulatory labeling due to the risk of severe adverse cardiac events. The concurrent use of alcohol with extended-release formulations may increase the rate and extent of Diltiazem absorption. In patients with hepatic or renal impairment, altered clearance can lead to increased Diltiazem plasma concentrations, affecting the clinical significance of other interactions. For intravenous administration, the solution must not be mixed with other medications due to documented physical incompatibilities.

How Zilden (Diltiazem) Works

Diltiazem acts as a non-dihydropyridine calcium channel blocker (CCB). Its core action is the modulation of calcium ion (Ca^2+) influx, which initiates muscle contraction and electrical signaling. The drug's primary biological target is the L-type voltage-gated calcium channel (L-VGCC) found on the membranes of cardiac myocytes and vascular smooth muscle cells. By binding to and blocking these channels, Diltiazem inhibits Ca^2+ entry, thereby interrupting the excitation-contraction coupling cascade in muscle cells.

In the vascular smooth muscle, the reduction of intracellular Ca^2+ induces muscle relaxation, which leads to the widening of blood vessels (vasodilation). This results in a decrease in the force required to propel blood, contributing to lower systemic vascular resistance (SVR).

Simultaneously, Diltiazem engages L-VGCCs within the heart's specialized conduction system, particularly the Sinoatrial (SA) and Atrioventricular (AV) nodes. Mechanistically, this action slows down the electrical impulse conduction and reduces the firing rate of the SA node. This leads to the physiological effects of slowing the heart rate (negative chronotropy) and prolonging the time between heartbeats (negative dromotropy).

Instructions for Using Diltiazem

The following describes the administration of Diltiazem (e.g., Zilden).

Administration Route	Dosage Form	Initial/Maintenance Dosing Rules
Oral	Immediate-Release (IR) Tablet	Initial dose is typically 30 mg, taken four times a day (before meals and at bedtime). Maintenance dosing is 180 mg to 360 mg per day in divided doses.
Oral	Extended-Release (ER) Capsule/Tablet	Initial dose is typically 120 mg to 240 mg taken once daily. Maintenance dosing ranges from 120 mg to 540 mg once daily, depending on the specific product formulation. Dose adjustments are generally made every 7 to 14 days.
Intravenous (IV)	Injection Solution	Initial bolus is 0.25 mg/kg administered over 2 minutes. A second bolus of 0.35 mg/kg may be given 15 minutes later. This is typically followed by a continuous infusion starting at 5 mg/hour, which is adjustable up to 15 mg/hour.

Specific Administration Rules

• ER Forms: Extended-Release capsules and tablets must be swallowed whole and must not be chewed, crushed, or opened (unless specifically instructed to sprinkle contents). Some ER capsules may be sprinkled onto applesauce and swallowed immediately.
• IR Tablets: The 30 mg tablet must not be split.
• Timing: Immediate-Release forms are often taken before meals and at bedtime. Timing for Extended-Release forms varies by product; some are taken on an empty stomach.
• Missed Dose: If a dose is missed, take it as soon as possible unless it is nearly time for the next scheduled dose. In that case, skip the missed dose and continue the regular schedule; do not double the dose.
• IV Administration: Intravenous administration requires the patient to be under continuous ECG monitoring and frequent blood pressure measurement. Infusions should generally not exceed 24 hours.

Research Evidence / Overview of Studies

Phase III Clinical Trials

Studies focused primarily on adult participants diagnosed with conditions such as chronic stable angina and hypertension. Research efforts have included exploring the biological processes that the drug may target, such as its influence on specific inflammatory markers, which followed initial laboratory and animal research.

• Trial Outcomes: Overall, research measured specific outcomes related to both angina and high blood pressure over periods of up to 12 weeks. Placebo-controlled trials monitored the primary symptom, assessing whether it changed during the trial, using validated rating scales.
  • Angina Measures: Studies evaluated changes in exercise tolerance and the frequency of chest pain episodes.
  • Hypertension Measures: Studies monitored reductions in systolic and diastolic blood pressure over 24-hour periods, with some focusing on specific timing of doses.

Safety and Adverse Events (AEs)

• Reported Side Effects: The most commonly reported adverse events across clinical studies included headache, dizziness, and mild gastrointestinal upset (such as constipation). The events were typically reported to be mild and did not last long.
• Laboratory Monitoring: In trials, researchers monitored liver function. Some participants experienced enzyme elevations. Studies excluded participants with a history of certain severe heart conditions, kidney impairment, or active infection.

Common questions about Zilden (Diltiazem) (FAQ)

Q: What color or shape are the standard Diltiazem tablets?

The physical appearance of Diltiazem tablets, including their color (e.g., orange or white) and shape (e.g., round), may vary depending on the dosage strength and the specific manufacturer. Official product labeling, such as that found on DailyMed, describes these physical details and corresponding imprint codes for identification.

Q: Is Diltiazem considered a "blood thinner" or an anticoagulant?

Diltiazem is classified as a Calcium Channel Blocker, which is different from a blood thinner (anticoagulant). Its primary action is relaxing blood vessels and slowing the heart rate, which helps to lower blood pressure, but it does not function to prevent blood clotting.

Q: How long does Diltiazem take to start working after the first dose?

Studies on the immediate-release form of Diltiazem show that detectable levels of the medicine can appear in the bloodstream relatively quickly, sometimes within 30 to 60 minutes after taking a dose. Peak plasma concentration, as described in product labeling, is generally reached about 2 to 4 hours after administration.

Q: Is there a risk of withdrawal symptoms if I stop taking Diltiazem suddenly?

Official instructions advise against abruptly stopping the use of Diltiazem. Regulatory information indicates that patients who are considering stopping this medicine should consult their healthcare provider for guidance on a safe approach.

Q: Does Diltiazem interact with grapefruit juice or other common foods?

Yes, official product information specifically notes that consuming grapefruit juice may lead to higher concentrations of Diltiazem in the body. This potential increase could enhance the effects of the medication. No similar interaction is universally noted for other common foods in the official label, but individuals can seek guidance from a healthcare professional regarding their diet.

Q: Does Diltiazem affect blood sugar levels, and is it safe for diabetics?

Diltiazem is indicated for heart-related conditions, and the product label does not specifically detail effects on blood sugar levels. However, official regulatory texts often advise that patients with co-existing conditions, such as diabetes, may require careful monitoring during treatment. Specific guidance on its safety for individuals with diabetes should be obtained from a healthcare provider.

Q: What is the maximum duration for an intravenous Diltiazem infusion?

For Diltiazem administered as a continuous intravenous (IV) infusion in a clinical setting, official prescribing information specifies that the infusion should generally not exceed 24 hours. This maximum duration is part of the established guidelines for the injectable product.

How to Store and Dispose of Zilden (Diltiazem)

Official regulatory guidelines define specific requirements for storing and disposing of Diltiazem products to maintain stability and ensure safety.

---

Storage Requirements

• Temperature: Oral forms (capsules/tablets) must be stored at Controlled Room Temperature (25 C / 77 F), permitting excursions between 15 C to 30 C. Injectable solutions typically require refrigeration (2 C to 8 C).
• Protection: The medicine must be stored in a tight, light-resistant container, and should be protected from freezing, excessive heat, and excessive humidity.
• Child Safety: Always keep Diltiazem out of the reach of children and store it with a child-resistant closure.

---

Handling and Disposal

• Handling: Do not crush or chew extended-release forms. Avoid contact with dust from broken products.
• Disposal: Do not keep outdated or unused medicine. Consult a healthcare professional or pharmacist for proper disposal methods and rules in your area. Unused portions of single-dose injectable vials must be discarded.